Imagion's chairman lends startup $150K in quick re-raise
What's the deal? Imagion BiosystemsDealroom has a profile for this one. Try Dealroom →, an ASX-listed clinical-stage cancer imaging company, has secured a US$150,000 loan from its executive chairman, Robert Proulx, to support working capital. The financing, announced July 28, 2026, is non-dilutive short-term debt the company can draw on as needed.
The terms: The unsecured loan carries 8.0% annual interest, charged only on funds actually drawn, with a four-month repayment term. Outstanding amounts may convert into ordinary shares, subject to conditions and any required shareholder or regulatory approvals.
Why now? The re-raise from an insider points to near-term cash needs. Proulx abstained from all board deliberations on the transaction, which the board says was struck on arm's length commercial terms and is in the interest of all shareholders.
What's the endgame? Imagion is developing MagSense, an MRI imaging agent that uses non-radioactive magnetic nanoparticles to detect cancer earlier. Its targets include HER2+ breast cancer, prostate cancers, and ovarian cancers.
What could go wrong? The loan is small and short-dated, covering only immediate working capital rather than a full runway. If drawn amounts convert to shares, existing holders could still face dilution down the line.
The signal: A modest, chairman-backed loan is a stopgap, not a growth round — a reminder that clinical-stage biotech firms often lean on insiders to bridge tight periods between larger raises.
Read more: listcorp.com
Image credit: Muffet
